Skip to main content
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · TARS ISIN · US87650L1035 US Manufacturing
Open in API
Filings indexed 576 across all filing types
Latest filing 2020-11-20 Board/Management Inform…
Country US United States of America
Listing US TARS

About Tarsus Pharmaceuticals, Inc.

https://www.tarsusrx.com/

Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for diseases with limited treatment options. The company's initial focus is on eye care. Its lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is the first and only FDA-approved treatment for Demodex blepharitis. Tarsus is also advancing a pipeline of potential treatments for other conditions with high unmet needs, including ocular rosacea, Lyme disease prevention, and other indications across dermatology and infectious diseases.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the appointment of a new director to the Board of Directors, including details about the director's term, committee assignment, and compensation. This matches the description of Board/Management Information filings, which cover announcements of changes in the company's board or senior management. The document is not a full annual report, earnings release, or other financial report, but a regulatory filing focused on management changes. Therefore, the appropriate classification is MANG (Board/Management Information). The document length and content support a high confidence level.
2020-11-20 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Tarsus Pharmaceuticals, Inc. It reports on an Investor Presentation given by the CEO at a healthcare conference. The text explicitly states that the presentation slides are filed as an exhibit and that the presentation is available on the company's website. The document does not contain detailed financial statements or analysis but rather announces and furnishes the investor presentation. The length is 4064 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, this is an Investor Presentation (IP) filing type.
2020-11-17 English
SC 13D
Major Shareholding Notification
2020-10-30 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-10-30 English
SCHEDULE 13G
Major Shareholding Notification
2020-10-28 English
Director's Dealing 2020
Director's Dealing
2020-10-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.